Bavarian Nordic Receives 1568 Million Order From Us For Additional Smallpox Vaccine Production

Bavarian Nordic Awarded Large Contract for Monkeypox Vaccine

Bavarian Nordic Receives $1,568 Million Order from US for Additional Smallpox Vaccine Production

Contract will support production of bulk vaccine for future supply of freeze-dried vaccines

WEB Bavarian Nordic AS announced today that it has received a new order valued at USD 1568 million from the US Biomedical Advanced Research and Development Authority (BARDA) for the production of additional bulk Smallpox vaccine. The contract will support the replenishment of inventory of bulk vaccine required for future manufacturing and supply of freeze-dried vaccines.

This contract follows Bavarian Nordic's recent commercial launch of JYNNEOS Smallpox and Monkeypox Vaccine Live Nonreplicating in the US. The vaccine is indicated for the prevention of smallpox and monkeypox in adults 18 years of age and older.